Table 1. Multivariable Cox regression analysis of factors prognostic for outcome in 476 neuroblastoma patientsa.
| Factors |
Event-free survival |
Overall survival |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| High LYAR expression (median level as the cut-off) | 1.47 (1.00–2.17) | <0.0001 | 3.22 (1.67–6.22) | 0.0005 |
| MYCN amplification | 1.80 (1.21–2.67) | 0.0035 | 2.68 (1.71–4.22) | <0.0001 |
| Age >18 months | 1.72 (1.18–2.52) | 0.0052 | 3.58 (1.98–6.48) | <0.0001 |
| Stages 3 and 4b | 2.50 (1.65–3.79) | <0.0001 | 2.99 (1.49–6.00) | 0.0021 |
| High LYAR expression (upper quartile as the cut-off) | 1.56 (1.03–2.35) | 0.0342 | 1.91 (1.13–3.22) | 0.0162 |
| MYCN amplification | 1.62 (1.05–2.49) | 0.0286 | 2.64 (1.59–4.37) | <0.0001 |
| Age >18 months | 1.67 (1.16–2.49) | 0.0064 | 3.73 (2.06–6.78) | <0.0001 |
| Stages 3 and 4b | 2.50 (1.65–3.78) | <0.0001 | 3.29 (1.64–6.60) | <0.0001 |
a
The level of LYAR expression was considered high or low in relation to the median or high quartile of expression in all tumours analysed. Hazard ratios were calculated as the antilogs of the regression coefficients in the proportional hazards regression. Multivariate Cox regression analysis was performed following the inclusion of the four above-listed factors into the Cox regression model, and P-value was obtained from two-sided log-rank test.
b
Tumour stage was categorized as favourable (International Neuroblastoma Staging System stages 1, 2 and 4S) or unfavorable (International Neuroblastoma Staging System stages 3 and 4)
.